COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

Clinical trial NCT06168032 · RECRUITING

Trial details

NCT number: NCT06168032
Sponsor: Peking Union Medical College Hospital
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

COVID-19 Recurrent Lung Cancer Vaccination Antibody Chemotherapy Immune Checkpoint Inhibitor

Start date: 2023-12-08
Primary completion: 2026-12-08
Enrollment: 1224

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.